References
- Bacher U, Schnittger S, Kern W, et al. The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia. Haematologica 2005;90:558–559.
- Moon HW, Chang YH, Kim TY, et al. Incidence of submicroscopic deletions vary according to disease entities and chromosomal translocations in hematologic malignancies: investigation by fluorescence in situ hybridization. Cancer Genet Cytogenet 2007; 175:166–168.
- Lee YK, Kim YR, Min HC, et al. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia. Cancer Genet Cytogenet 2006;166:65–73.
- Godon C, Proffitt J, Dastugue N, et al. Large deletions 5’ to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia. Leukemia 2002;16:1752–1754.
- Egan N, O’Reilly J, Chipper L, et al. Deletion of CBFB in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16. Cancer Genet Cytogenet 2004;154:60–62.
- Arber DA, Chang KL, Lyda MH, et al. Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. Hum Pathol 2003;34:809–813.
- Berger R, Busson M, Baranger L, et al. Loss of the NPM1 gene in myeloid disorders with chromosome 5 rearrangements. Leukemia 2006;20:319–321.
- Shaffer LG, Slovak ML, Campbell LJ. ISCN 2009: an international system for human cytogenetic nomenclature (2009). Basel: Karger Medical Scientific; 2009.
- Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005;437: 147–153.
- Dumezy F, Renneville A, Mayeur-Rousse C, et al. Acute myeloid leukemia with translocation t(3;5): new molecular insights. Haematologica 2013;98:e52–e54.
- Lee WH, Salek-Ardakani S, Pandolfi PP, et al. NPM-MLF1 synergizes with Npm haploinsufficiency to enhance myeloid progenitor activity. Leukemia 2012;26:1110–1112.
- Matsumoto N, Yoneda-Kato N, Iguchi T, et al. Elevated MLF1 expression correlates with malignant progression from myelodysplastic syndrome. Leukemia 2000;14:1757–1765.
- Schmidt B, Liebenberg V, Dietrich D, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 2010;10:600.
- Kneip C, Schmidt B, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol 2011;6:1632–1638.
- Peng L, Yanjiao M, Ai-guo W, et al. A fine balance between CCNL1 and TIMP1 contributes to the development of breast cancer cells. Biochem Biophys Res Commun 2011;409:344–349.